CeriBell (NASDAQ:CBLL) CEO Xingjuan Chao Sells 2,084 Shares

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 2,084 shares of the firm’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $19.79, for a total transaction of $41,242.36. Following the completion of the sale, the chief executive officer owned 725,164 shares of the company’s stock, valued at $14,350,995.56. This trade represents a 0.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Xingjuan Chao also recently made the following trade(s):

• On Monday, January 5th, Xingjuan Chao sold 79,000 shares of CeriBell stock. The shares were sold at an average price of $21.27, for a total value of $1,680,330.00.
• On Thursday, December 4th, Xingjuan Chao sold 25,000 shares of CeriBell stock. The stock was sold at an average price of $18.82, for a total transaction of $470,500.00.
• On Monday, December 1st, Xingjuan Chao sold 25,000 shares of CeriBell stock. The shares were sold at an average price of $16.59, for a total value of $414,750.00.

CeriBell Stock Up 0.4%

Shares of NASDAQ CBLL traded up $0.08 during trading hours on Thursday, hitting $19.03. 134,108 shares of the stock were exchanged, compared to its average volume of 345,471. The firm has a fifty day moving average price of $21.20 and a 200-day moving average price of $16.19. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12. CeriBell, Inc. has a 12 month low of $10.01 and a 12 month high of $25.37. The company has a market cap of $706.01 million, a PE ratio of -12.90 and a beta of 1.03.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.07. CeriBell had a negative return on equity of 30.99% and a negative net margin of 59.97%.The business had revenue of $24.78 million for the quarter, compared to the consensus estimate of $23.95 million. On average, sell-side analysts expect that CeriBell, Inc. will post -2.46 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. BTIG Research reaffirmed a “buy” rating and set a $30.00 price target on shares of CeriBell in a research report on Wednesday, January 28th. Canaccord Genuity Group upped their price objective on CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. TD Cowen reaffirmed a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. Finally, JPMorgan Chase & Co. decreased their price target on CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $24.67.

Institutional Investors Weigh In On CeriBell

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp increased its holdings in shares of CeriBell by 1,945.9% in the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock valued at $26,797,000 after acquiring an additional 1,162,200 shares during the period. KCM Capital Inc purchased a new position in shares of CeriBell during the 4th quarter worth approximately $21,930,000. Royce & Associates LP purchased a new position in CeriBell in the 4th quarter valued at about $11,695,000. Adage Capital Partners GP L.L.C. purchased a new position in shares of CeriBell during the 4th quarter worth about $10,965,000. Finally, CenterBook Partners LP raised its stake in shares of CeriBell by 448.0% in the 3rd quarter. CenterBook Partners LP now owns 476,554 shares of the company’s stock valued at $5,476,000 after acquiring an additional 389,584 shares during the period.

Trending Headlines about CeriBell

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Q4 beat on EPS and revenue — CeriBell reported Q4 EPS of ($0.36) vs. a consensus of ($0.43) and revenue of $24.78M vs. $23.95M expected, a beat that supports the recent uptick in the share price. MarketBeat: Q4 Results & Conference Call
• Positive Sentiment: FY‑2026 revenue guidance provided — Management gave revenue guidance of roughly $111M–$115M for FY‑2026, which is close to consensus (~$112.7M), offering a clearer growth target for the year. Business Insider: Full Year Results & Guidance
• Positive Sentiment: Earnings call highlighted revenue surge and market expansion — Management commentary and the call transcript emphasized accelerating revenue and expansion into new markets, supporting upside potential if execution continues. Yahoo Finance: Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Short‑interest data appears unreliable this cycle — the published short‑interest entry shows zero shares / NaN change, which is likely a reporting artifact and provides no actionable signal today.
• Negative Sentiment: Multiple insider sales disclosed — several senior executives (CEO Xingjuan Chao, CFO Scott Blumberg, CTO Raymond Woo, CRO Joseph Manni and a VP) sold small amounts of stock at roughly $19.79–$19.98, reducing their positions by fractions of a percent; while sizes are modest relative to total holdings, clustered insider selling can create short‑term investor concern. InsiderTrades: Xingjuan Chao Sale SEC Filing: CEO Ownership

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.